Page 194 - Read Online

Lai et al. Imbalance of NK and B cell subsets in GMG exacerbation

10. Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with 28. Shibatomi K, Ida H, Yamasaki S, Nakashima T, Origuchi T, Kawakami
ryanodine receptor antibodies have distinctive clinical features. Euro A, Migita K, Kawabe Y, Tsujihata M, Anderson P, Eguchi K. A novel
J Neurol 2007;14:617-20. role for interleukin-18 in human natural killer cell death: high serum
11. Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann levels and low natural killer cell numbers in patients with systemic
RL, Maselli RA, Schnier J, Agius MA. Acute severe animal model of autoimmune diseases. Arthritis Rheum 2001;44:884-92.
anti-muscle-specific kinase myasthenia: combined postsynaptic and 29. Trinchieri G. Biology of natural killer cells. Adv Immunol
presynaptic changes. Arch Neurol 2012;69:453-60. 1989;47:187-376.
12. Li WX, Pan HF, Hu JL, Wang CZ, Zhang N, Li J, Li XP, Xu JH, Ye 30. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells
DQ. Assay of T- and NK-cell subsets and the expression of NKG2A balance immune responses during inflammation, autoimmunity, and
and NKG2D in patients with new-onset systemic lupus erythematosus. cancer. Ann N Y Acad Sci 2010;1183:38-57.
Clin Rheumatol 2010;29:315-23. 31. Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory
13. Caldwell CW, Bridges AJ, Walker SE, Smarr KL, Reichert RJ, B cells (B10 cells) in autoimmune disease. Arthritis Res Ther
Anderson SK, Hewett JE, Parker JC. A controlled study of lymphocyte 2013;15 Suppl 1:S1.
subsets in rheumatoid arthritis. Clin Immunol Immunopathol 32. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol
1992;63:237-44. 2006;176:705-10.
14. Goto Y, Itoh M, Ogawa N, Goto Y, Ohashi H, Ohno R. Increased 33. Sheng JR, Quan S, Soliven B. CD1d(hi)CD5+ B cells expanded by
production of B cell growth factor (BCGF) in Sjogren’s syndrome. J GM-CSF in vivo suppress experimental autoimmune myasthenia
Autoimmun 1996;9:545-50. gravis. J Immunol 2014;193:2669-77.
15. Szodoray P, Gal I, Barath S, Aleksza M, Horvath IF, Gergely P Jr, 34. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA,
Szegedi G, Nakken B, Zeher M. Immunological alterations in newly Ehrenstein MR, Mauri C. CD19(+)CD24(hi)CD38(hi) B cells
diagnosed primary Sjogren’s syndrome characterized by skewed exhibit regulatory capacity in healthy individuals but are functionally
peripheral T-cell subsets and inflammatory cytokines. Scand J impaired in systemic Lupus Erythematosus patients. Immunity
Rheumatol 2008;37:205-12. 2010;32:129-40.
16. Chien PJ, Yeh JH, Shih CM, Hsueh YM, Chen MC, Chiu HC. A 35. Sun F, Ladha SS, Yang L, Liu Q, Shi SX, Su N, Bomprezzi R, Shi
decrease in the percentage of CD3+ cells is correlated with clinical FD. Interleukin-10 producing-B cells and their association with
improvement during plasmapheresis in patients with myasthenia responsiveness to rituximab in myasthenia gravis. Muscle Nerve
gravis. Artif Organs 2013;37:211-6. 2014;49:487-94.
17. Li X, Xiao BG, Xi JY, Lu CZ, Lu JH. Decrease of CD4(+)CD25(high) 36. Zha B, Wang L, Liu X, Liu J, Chen Z, Xu J, Sheng L, Li Y, Chu
Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) Y. Decrease in proportion of CD19+ CD24(hi) CD27+ B cells and
B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol impairment of their suppressive function in Graves’ disease. PLoS
2008;126:180-8. One 2012;7:e49835.
18. Suzuki Y, Onodera H, Tago H, Saito R, Ohuchi M, Shimizu M, 37. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC,
Matsumura Y, Kondo T, Yoshie O, Itoyama Y. Altered expression of Penn AS, Sanders DB. Myasthenia gravis: recommendations for
Th1-type chemokine receptor CXCR3 on CD4+ T cells in myasthenia clinical research standards. Task Force of the Medical Scientific
gravis patients. J Neuroimmunol 2006;172:166-74. Advisory Board of the Myasthenia Gravis Foundation of America.
19. Teleshova N, Matusevicius D, Kivisakk P, Mustafa M, Pirskanen R, Ann Thorac Surg 2000;70:327-34.
Link H. Altered expression of costimulatory molecules in myasthenia 38. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF.
gravis. Muscle Nerve 2000;23:946-53. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype
20. Conti-Fine BM, Milani M, Wang W. CD4+ T cells and cytokines in controls T cell-dependent inflammatory responses. Immunity
the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 2008;28:639-50.
2008;1132:193-209. 39. Liu C, Wang Q, Qiu Z, Lin J, Chen B, Li Y, Gui M, Zhang M, Yang M,
21. Masuda M, Matsumoto M, Tanaka S, Nakajima K, Yamada N, Ido Wang W, Bu B. Analysis of mortality and related factors in 2195 adult
N, Ohtsuka T, Nishida M, Hirano T, Utsumi H. Clinical implication myasthenia gravis patients in a 10-year follow-up study. Neurol India
of peripheral CD4+CD25+ regulatory T cells and Th17 cells in 2017;65:518-24.
myasthenia gravis patients. J Neuroimmunol 2010;225:123-31. 40. Yu S, Li F, Chen B, Lin J, Yang M, Fu X, Li J, Bu B. Eight-year
22. Han J, Sun L, Fan X, Wang Z, Cheng Y, Zhu J, Jin T. Role of follow-up of patients with myasthenia gravis after thymectomy. Acta
regulatory b cells in neuroimmunologic disorders. J Neurosci Res Neurol Scand 2015;131:94-101.
2016;94:693-701. 41. Gui M, Luo X, Lin J, Li Y, Zhang M, Zhang X, Yang M, Wang W,
23. Loza MJ, Zamai L, Azzoni L, Rosati E, Perussia B. Expression of Bu B. Long-term outcome of 424 childhood-onset myasthenia gravis
type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) patients. J Neurol 2015;262:823-30.
cytokines at distinct stages of natural killer cell differentiation from 42. Yu S, Lin J, Fu X, Li J, Li Y, Chen B, Yang M, Zhang M, Bu B.
progenitor cells. Blood 2002;99:1273-81. Risk factors of myasthenic crisis after thymectomy in 178 generalized
24. French AR, Yokoyama WM. Natural killer cells and autoimmunity. myasthenia gravis patients in a five-year follow-up study. Int J
Arthritis Res Ther 2004;6:8-14. Nneurosci 2014;124:792-8.
25. Shi FD, Ljunggren HG, Sarvetnick N. Innate immunity and 43. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp
autoimmunity: from self-protection to self-destruction. Trends Immunol 2014;175:408-18.
Immunol 2001;22:97-101. 44. Joao C, Ogle BM, Gay-Rabinstein C, Platt JL, Cascalho M. B cell-
26. Zimmer J, Bausinger H, de la Salle H. Autoimmunity mediated by dependent TCR diversification. J Immunol 2004;172:4709-16.
innate immune effector cells. Trends Immunol 2001;22:300-1. 45. Ngo VN, Cornall RJ, Cyster JG. Splenic T zone development is B cell
27. Grom AA. Natural killer cell dysfunction: a common pathway in dependent. J Exp Med 2001;194:1649-60.
systemic-onset juvenile rheumatoid arthritis, macrophage activation 46. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser
syndrome, and hemophagocytic lymphohistiocytosis? Arthritis M. B lymphocytes regulate dendritic cell (DC) function in vivo:
Rheum 2004;50:689-98. increased interleukin 12 production by DCs from B cell-deficient mice
186 Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ September 18, 2017